Search

The Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France on April 22, 2020. The Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris , France on April 22, ...

... whistleblowers eligible for payouts under the program. This has to be one of the sloppiest regulations I have ever seen, he said. In the case in D.C. , two anonymous whistleblowers claimed they were entitled to awards from the SEC's $25 million settlement with Novartis AG in 2016 over allegations that the drugmaker bribed Chinese healthcare providers. The company did not admit to wrongdoing. The pair said they were the sources behind articles in 2013 alleging similar violations by two of Novartis ' competitors....

... of leprosy cases, and most of it is due to lack of awareness and challenges relating to accessibility for diagnosis and treatment. The delay in detection can cause nerve damage in patients, and is critical for a timely detection of this condition. Novartis has extended its MoU with the WHO to 2,025 to donate the global supply of leprosy drugs completely free of charge.

... to re-shape its portfolio. There is no certainty that an agreement will be reached. In mid- 2022, GSK is planning to spin off the unit, known as the painkiller Advil, Sensodyne toothpaste and Tums. After integrating the consumer health businesses of Novartis 2015 and Pfizer 2019 GSK said it had annual sales of 9.6 billion pounds $13.1 billion in 2021. Consumer goods conglomerate Unilever sells a wide variety of consumer products, from Hellmann's mayonnaise to Lipton tea and Ben Jerry's ice cream....

Swiss drugmaker Novartis is seen at the company's plant in the northern Swiss town of Stein, Switzerland on October 23, Reuters AZURich, Jan 10, Reuters Reuterskus, Reuters Swiss drugmaker Novartis is seen at the company's plant in the northern Swiss town of Stein,...

... Suisse in November. According to the bank, significantly higher M&A and ECM pipelines are expected to sustain momentum in the business. According to Bloomberg, 7 deals advisers were working on $329 billion of transactions in 2021. In addition to that, Novartis AG s agreement to sell its stake in Roche Holding AG for $20.7 billion, Veolia Environnement SA's takeover of Suez SA worth $15 billion and Australian biotech CSL Ltd. s agreement to acquire Swiss drugmaker Vifor Pharma AG for almost $12 billion ...

... aimed at resolving tensions, with Russian troops stationed on the border of Ukraine . The spending package that Sen. Joe Manchin , the West Virginia Democrat, proposed to the White House is no longer on the table, according to the Washington Post. Novartis NVS plans to file for Food and Drug Administration approval for a COVID 19 treatment it licensed from Molecular Partners MOLN, after a Phase 2 trial showed a 78% reduction in hospitalization. Apparel maker Lululemon Athletica LULU warned that ...

ZURich, Dec 11, Reuters - Novartis is seeing strong interest from private equity investors as well as other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Narasimhan said in a newspaper interview. ZURICH, Dec 11,...